v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($)
Total
Common Class A
Total Shareholders' Equity
Common Stock
Common Class A
Common Stock
Common Class C
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Noncontrolling Interests
Common stock, beginning balance (in shares) at Dec. 31, 2024       63,077,431 841,269        
Equity, beginning balance at Dec. 31, 2024 $ 453,391,000   $ 446,825,000 $ 6,000 $ 0 $ 677,415,000 $ (235,593,000) $ 4,997,000 $ 6,566,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Share-based compensation under the Employee Share Participation Plan and MoonLake Immunotherapeutics 2022 Equity Incentive Plan 2,290,000   2,279,000     2,279,000     11,000
Conversion of MoonLake class C ordinary shares into class A ordinary shares (in shares)       111,949 (111,949)        
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares 0   851,000     841,000   10,000 (851,000)
Option exercised and converted under the employee stock option plan, net of stamp duty fee (in shares)       93,347          
Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee 120,000   129,000     129,000     (9,000)
Issuance of class A ordinary shares, net of transaction costs   191,526              
Net loss (40,559,000)   (39,944,000)       (39,944,000)   (615,000)
Other comprehensive loss (2,661,000)   (2,620,000)         (2,620,000) (41,000)
Common stock, ending balance (in shares) at Mar. 31, 2025       63,474,253 729,320        
Equity, end balance at Mar. 31, 2025 412,581,000   407,520,000 $ 6,000 $ 0 680,664,000 (275,537,000) 2,387,000 $ 5,061,000
Common stock, beginning balance (in shares) at Dec. 31, 2025   71,373,579   71,373,579          
Equity, beginning balance at Dec. 31, 2025     304,481,000 $ 7,000   766,781,000 (462,911,000) 604,000  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Share-based compensation under the Employee Share Participation Plan and MoonLake Immunotherapeutics 2022 Equity Incentive Plan     13,355,000     13,355,000      
Option exercised and converted under the employee stock option plan, net of stamp duty fee (in shares)       69,632          
Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee     170,000     170,000      
Issuance of class A ordinary shares, net of transaction costs   354,296              
Issuance of Class A Ordinary Shares, net of transaction costs (in shares)       336,559          
Issuance of Class A Ordinary Shares, net of transaction costs     6,007,000     6,007,000      
Net loss (69,707,000)   (69,707,000)       (69,707,000)    
Other comprehensive loss $ (282,000)   (282,000)         (282,000)  
Common stock, ending balance (in shares) at Mar. 31, 2026   72,134,066   72,134,066 0        
Equity, end balance at Mar. 31, 2026     $ 254,024,000 $ 7,000   $ 786,313,000 $ (532,618,000) $ 322,000